{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T15:12:44Z","timestamp":1782659564130,"version":"3.54.5"},"reference-count":29,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1,1]]},"abstract":"<jats:title>This Clinical Report was retired June 2024.<\/jats:title>\n               <jats:p>The American Academy of Pediatrics strongly supports the Polio Eradication and Endgame Strategic Plan of the Global Polio Eradication Initiative. This plan was endorsed in November 2012 by the Strategic Advisory Group of Experts on Immunization of the World Health Organization and published by the World Health Organization in April 2013. As a key component of the plan, it will be necessary to stop oral polio vaccine (OPV) use globally to achieve eradication, because the attenuated viruses in the vaccine rarely can cause polio. The plan includes procedures for elimination of vaccine-associated paralytic polio and circulating vaccine-derived polioviruses (cVDPVs). cVDPVs can proliferate when vaccine viruses are transmitted among susceptible people, resulting in mutations conferring both the neurovirulence and transmissibility characteristics of wild polioviruses. Although there are 3 different types of wild poliovirus strains, the polio eradication effort has already resulted in the global elimination of type 2 poliovirus for more than a decade. Type 3 poliovirus may be eliminated because the wild type 3 poliovirus was last detected in 2012. Thus, of the 3 wild types, only wild type 1 poliovirus is still known to be circulating and causing disease. OPV remains the key vaccine for eradicating wild polioviruses in polio-infected countries because it induces high levels of systemic immunity to prevent paralysis and intestinal immunity to reduce transmission. However, OPV is a rare cause of paralysis and the substantial decrease in wild-type disease has resulted in estimates that the vaccine is causing more polio-related paralysis annually in recent years than the wild virus. The new endgame strategic plan calls for stepwise removal of the type 2 poliovirus component from trivalent oral vaccines, because type 2 wild poliovirus appears to have been eradicated (since 1999) and yet is the main cause of cVDPV outbreaks and approximately 40% of vaccine-associated paralytic polio cases. The Endgame and Strategic Plan will be accomplished by shifting from trivalent OPV to bivalent OPV (containing types 1 and 3 poliovirus only). It will be necessary to introduce trivalent inactivated poliovirus vaccine (IPV) into routine immunization programs in all countries using OPV to provide population immunity to type 2 before the switch from trivalent OPV to bivalent OPV. The Global Polio Eradication Initiative hopes to achieve global eradication of polio by 2018 with this strategy, after which all OPV use will be stopped. Challenges expected for adding IPV into routine immunization schedules include higher cost of IPV compared with OPV, cold-chain capacity limits, more complex administration of vaccine because IPV requires injections as opposed to oral administration, and inferior intestinal immunity conferred by IPV. The goal of this report is to help pediatricians understand the change in strategy and outline ways that pediatricians can help global polio eradication efforts, including advocating for the resources needed to accomplish polio eradication and for incorporation of IPV into routine immunization programs in all countries.<\/jats:p>","DOI":"10.1542\/peds.2014-3163","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T01:30:05Z","timestamp":1419903005000},"source":"Crossref","is-referenced-by-count":18,"title":["Eradicating Polio: How the World\u2019s Pediatricians Can Help Stop This Crippling Illness Forever"],"prefix":"10.1542","volume":"135","author":[{"given":"Walter A.","family":"Orenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"THE COMMITTEE ON INFECTIOUS DISEASES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2015,1,1]]},"reference":[{"key":"2024062712261830900_B1","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/B978-1-4557-0090-5.00035-5","article-title":"Poliovirus vaccine\u2014live","volume-title":"Vaccines","author":"Sutter","year":"2013","edition":"6th ed."},{"issue":"11","key":"2024062712261830900_B2","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/aje\/kwq320","article-title":"From emergence to eradication: the epidemiology of poliomyelitis deconstructed","volume":"172","author":"Nathanson","year":"2010","journal-title":"Am J Epidemiol"},{"key":"2024062712261830900_B3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/B978-1-4557-0090-5.00034-3","article-title":"Poliovirus vaccine\u2014inactivated","volume-title":"Vaccines","author":"Vidor","year":"2013","edition":"6th ed."},{"issue":"1623","key":"2024062712261830900_B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1098\/rstb.2012.0140","article-title":"The final stages of the global eradication of poliomyelitis","volume":"368","author":"Grassly","year":"2013","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"5","key":"2024062712261830900_B5","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1086\/605330","article-title":"Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India","volume":"200","author":"Grassly","year":"2009","journal-title":"J Infect Dis"},{"issue":"5","key":"2024062712261830900_B6","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/clinids\/13.5.926","article-title":"Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review","volume":"13","author":"Patriarca","year":"1991","journal-title":"Rev Infect Dis"},{"key":"2024062712261830900_B7","unstructured":"Global Polio Eradication Initiative. Polio this week: as of October 28, 2014. Available at:\u2008www.polioeradication.org\/Dataandmonitoring\/Poliothisweek.aspx. Accessed October 28, 2014"},{"issue":"21","key":"2024062712261830900_B8","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1056\/NEJMe1311591","article-title":"No country is safe without global eradication of poliomyelitis","volume":"369","author":"Mundel","year":"2013","journal-title":"N Engl J Med"},{"key":"2024062712261830900_B9","unstructured":"Global Polio Eradication Initiative. Supplementary immunization. Available at:\u2008www.polioeradication.org\/Aboutus\/Strategy\/Supplementaryimmunization.aspx. Accessed April 7, 2014"},{"issue":"8","key":"2024062712261830900_B10","doi-asserted-by":"crossref","first-page":"624","DOI":"10.2471\/BLT.08.060863","article-title":"Achieving polio eradication: a review of health communication evidence and lessons learned in India and Pakistan","volume":"87","author":"Obreg\u00f3n","year":"2009","journal-title":"Bull World Health Organ"},{"issue":"suppl 4","key":"2024062712261830900_B11","doi-asserted-by":"crossref","first-page":"D80","DOI":"10.1016\/j.vaccine.2011.10.005","article-title":"The global polio eradication initiative: lessons learned and prospects for success","volume":"29","author":"Aylward","year":"2011","journal-title":"Vaccine"},{"issue":"24","key":"2024062712261830900_B12","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1056\/NEJMp1104329","article-title":"The polio endgame","volume":"364","author":"Aylward","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"2024062712261830900_B13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/clinids\/14.2.568","article-title":"Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease","volume":"14","author":"Strebel","year":"1992","journal-title":"Clin Infect Dis"},{"key":"2024062712261830900_B14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJMp1808903","article-title":"Ending use of oral poliovirus vaccine: a difficult move in the polio endgame","volume":"3799","author":"Pallansch","year":"2018","journal-title":"N Engl J Med"},{"issue":"9753","key":"2024062712261830900_B15","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/S0140-6736(10)61230-5","article-title":"Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial","volume":"376","author":"Sutter","year":"2010","journal-title":"Lancet"},{"key":"2024062712261830900_B16","first-page":"217","article-title":"Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 & 2003","volume":"118","author":"Deshpande","year":"2003","journal-title":"Indian J Med Res"},{"issue":"9","key":"2024062712261830900_B17","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1716677","article-title":"Type 2 poliovirus detection after global withdrawal of trivalent oral vaccine","volume":"379","author":"Blake","year":"2018","journal-title":"N Engl J Med"},{"key":"2024062712261830900_B18","volume-title":"IPV recommended for countries to mitigate risks and consequences associated with OPV2 withdrawal","author":"World Health Organization","year":"2012"},{"issue":"6","key":"2024062712261830900_B19","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/infdis\/162.6.1291","article-title":"Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses","volume":"162","author":"Faden","year":"1990","journal-title":"J Infect Dis"},{"issue":"2","key":"2024062712261830900_B20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S1473-3099(11)70190-6","article-title":"Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a communitybased, randomised controlled trial","volume":"12","author":"Est\u00edvariz","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"8860","key":"2024062712261830900_B21","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/0140-6736(93)90693-B","article-title":"Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine","volume":"341","author":"Moriniere","year":"1993","journal-title":"Lancet"},{"key":"2024062712261830900_B22","volume-title":"Polio Eradication & Endgame Strategic Plan 2013-2018","author":"Global Polio Eradication Initiative","year":"2013"},{"key":"2024062712261830900_B23","volume-title":"7th Meeting of the SAGE Polio Working Group: note for the record","author":"World Health Organization","year":"2013"},{"issue":"4","key":"2024062712261830900_B24","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1539-6924.2012.01864.x","article-title":"Expert review on poliovirus immunity and transmission","volume":"33","author":"Duintjer Tebbens","year":"2013","journal-title":"Risk Anal"},{"issue":"2","key":"2024062712261830900_B25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.vaccine.2010.10.026","article-title":"Economic analysis of the global polio eradication initiative","volume":"29","author":"Duintjer Tebbens","year":"2010","journal-title":"Vaccine"},{"issue":"27","key":"2024062712261830900_B26","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1016\/j.vaccine.2013.04.024","article-title":"Scientific Experts Against Polio. Scientific declaration on polio eradication","volume":"31","author":"Bhutta","year":"2013","journal-title":"Vaccine"},{"issue":"9570","key":"2024062712261830900_B27","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(07)60532-7","article-title":"Eradication versus control for poliomyelitis: an economic analysis","volume":"369","author":"Thompson","year":"2007","journal-title":"Lancet"},{"key":"2024062712261830900_B28","unstructured":"Scientific Experts Against Polio. Scientific declaration on polio eradication. Available at: http:\/\/vaccines.emory.edu\/poliodeclaration\/text.pdf. Accessed April 7, 2014"},{"key":"2024062712261830900_B29","unstructured":"Centers for Disease Control and Prevention. Polio: for Travelers. Available at: http:\/\/www.cdc.gov\/polio\/us\/travelers.html. Accessed November 3, 2014"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2014-3163\/1671424\/peds_2014-3163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2014-3163\/1671424\/peds_2014-3163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T12:26:52Z","timestamp":1719491212000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/135\/1\/e20143163\/52925\/Eradicating-Polio-How-the-World-s-Pediatricians"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,1,1]]},"published-print":{"date-parts":[[2015,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2014-3163","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,1]]},"article-number":"e20143163"}}